Parkinson's disease subtypes show a specific link between dopaminergic and glucose metabolism in the striatum

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Eggers, Carsten ^a   Schwartz, Frank ^a   Pedrosa, David J ^a   Kracht, Lutz ^b   Timmermann, Lars ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPAMINE F 18; DOPAMINE; FLUORODEOXYGLUCOSE F 18; GLUCOSE; 6 FLUORODOPA F 18; DOPA; RADIOPHARMACEUTICAL AGENT;

ADULT; AKINESIA; ARTICLE; BRAIN METABOLISM; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; FEMALE; GLUCOSE METABOLISM; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PUTAMEN; RETROSPECTIVE STUDY; TREMOR; AGED; ANALOGS AND DERIVATIVES; DIAGNOSTIC USE; DOPAMINERGIC NERVE CELL; METABOLISM; MIDDLE AGED; PATHOLOGY; SCINTISCANNING; VENTRAL STRIATUM;

AGED; DIHYDROXYPHENYLALANINE; DOPAMINE; DOPAMINERGIC NEURONS; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; VENTRAL STRIATUM;

EID: 84901373835     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096629     Document Type: Article

References (36)

1. Jankovic J, Kapadia AS (2001) Functional decline in Parkinson disease. Arch Neurol 58: 1611-1615. (Pubitemid 32963225)
2. Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, et al. (1990) Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40: 1529-1534. (Pubitemid 20351344)
3. Rajput AH, Voll A, Rajput ML, Robinson CA, Rajput A (2009) Course in Parkinson disease subtypes: A 39-year clinicopathologic study. Neurology 73: 206-212.
4. van Rooden SM, Colas F, Martinez-Martin P, Visser M, Verbaan D, et al. (2011) Clinical subtypes of Parkinson's disease. Mov Disord 26: 51-58.
5. Rosenberg-Katz K, Herman T, Jacob Y, Giladi N, Hendler T, et al. (2013) Gray matter atrophy distinguishes between Parkinson disease motor subtypes. Neurology 80: 1476-1484.
6. Herman T, Rosenberg-Katz K, Jacob Y, Auriel E, Gurevich T, et al. (2013) White matter hyperintensities in Parkinson's disease: do they explain the disparity between the postural instability gait difficulty and tremor dominant subtypes? PLoS One 8: e55193.
7. Eggers C, Kahraman D, Fink GR, Schmidt M, Timmermann L (2011) Akinetic-rigid and tremor-dominant Parkinson's disease patients show different patterns of FP-CIT Single photon emission computed tomography. Mov Disord 26: 416-423.
8. Eggers C, Pedrosa DJ, Kahraman D, Maier F, Lewis CJ, et al. (2012) Parkinson subtypes progress differently in clinical course and imaging pattern. PLoS One 7: e46813.
9. Eckert T, Tang C, Eidelberg D (2007) Assessment of the progression of Parkinson's disease: a metabolic network approach. Lancet Neurol 6: 926-932. (Pubitemid 47405003)
10. Mure H, Hirano S, Tang CC, Isaias IU, Antonini A, et al. (2011) Parkinson's disease tremor-related metabolic network: characterization, progression, and treatment effects. Neuroimage 54: 1244-1253.
11. Lozza C, Marie RM, Baron JC (2002) The metabolic substrates of bradykinesia and tremor in uncomplicated Parkinson's disease. Neuroimage 17: 688-699. (Pubitemid 35317004)
12. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, et al. (2010) Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 25: 2649-2653.
13. Ghaemi M, Raethjen J, Hilker R, Rudolf J, Sobesky J, et al. (2002) Monosymptomatic resting tremor and Parkinson's disease: a multitracer positron emission tomographic study. Mov Disord 17: 782-788. (Pubitemid 41295025)
14. Dhawan V, Ma Y, Pillai V, Spetsieris P, Chaly T, et al. (2002) Comparative analysis of striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach. J Nucl Med 43: 1324-1330.
15. Alexander GE, DeLong MR, Strick PL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9: 357-381. (Pubitemid 16055790)
16. Hallett M (2012) Parkinson's disease tremor: pathophysiology. Parkinsonism Relat Disord 18 Suppl 1: S85-86.
17. Benninger DH, Thees S, Kollias SS, Bassetti CL, Waldvogel D (2009) Morphological differences in Parkinson's disease with and without rest tremor. J Neurol 256: 256-263.
18. Kostic VS, Agosta F, Pievani M, Stefanova E, Jecmenica-Lukic M, et al. (2012) Pattern of brain tissue loss associated with freezing of gait in Parkinson disease. Neurology 78: 409-416.
19. Rosenberg-Katz K, Herman T, Jacob Y, Giladi N, Hendler T, et al. (2013) Gray matter atrophy distinguishes between Parkinson disease motor subtypes. Neurology 80: 1476-1484.
20. Kassubek J, Juengling FD, Hellwig B, Spreer J, Lucking CH (2002) Thalamic gray matter changes in unilateral Parkinsonian resting tremor: a voxel-based morphometric analysis of 3-dimensional magnetic resonance imaging. Neurosci Lett 323: 29-32. (Pubitemid 34241612)
21. Rossi C, Frosini D, Volterrani D, De Feo P, Unti E, et al. (2010) Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study. Eur J Neurol 17: 626-630.
22. Eggers C, Hilker R, Burghaus L, Schumacher B, Heiss WD (2009) High resolution positron emission tomography demonstrates basal ganglia dysfunction in early Parkinson's disease. J Neurol Sci 276: 27-30.
23. Jellinger KA (1999) Post mortem studies in Parkinson's disease - is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl 56: 1-29.
24. Borghammer P, Hansen SB, Eggers C, Chakravarty M, Vang K, et al. (2012) Glucose metabolism in small subcortical structures in Parkinson's disease. Acta Neurol Scand 125: 303-310.
25. Borghammer P, Cumming P, Aanerud J, Forster S, Gjedde A (2009) Subcortical elevation of metabolism in Parkinson's disease - a critical reappraisal in the context of global mean normalization. Neuroimage 47: 1514-1521.
26. Hu MT, Taylor-Robinson SD, Chaudhuri KR, Bell JD, Labbe C, et al. (2000) Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. Brain 123 (Pt 2): 340-352. (Pubitemid 30055157)
27. Peppard RF, Martin WR, Carr GD, Grochowski E, Schulzer M, et al. (1992) Cerebral glucose metabolism in Parkinson's disease with and without dementia. Arch Neurol 49: 1262-1268.
28. Baron JC (1994) [Consequences of lesions of the basal ganglia on cerebral metabolic activity: clinical implications]. Rev Neurol (Paris) 150: 599-604.
29. Ma Y, Dhawan V, Mentis M, Chaly T, Spetsieris PG, et al. (2002) Parametric mapping of [18F]FPCIT binding in early stage Parkinson's disease: a PET study. Synapse 45: 125-133. (Pubitemid 34742948)
30. Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, et al. (2005) Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 65: 1716-1722.
31. Jokinen P, Bruck A, Aalto S, Forsback S, Parkkola R, et al. (2009) Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord 15: 88-93.
32. Polito C, Berti V, Ramat S, Vanzi E, De Cristofaro MT, et al. (2012) Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinson's disease. Neurobiol Aging 33: 206 e229-239.
33. Halliday GM, McCann H (2010) The progression of pathology in Parkinson's disease. Ann N Y Acad Sci 1184: 188-195.
34. Niethammer M, Tang CC, Ma Y, Mattis PJ, Ko JH, et al. (2013) Parkinson's disease cognitive network correlates with caudate dopamine. Neuroimage 78: 204-209.
35. Kaasinen V, Maguire RP, Hundemer HP, Leenders KL (2006) Corticostriatal covariance patterns of 6-[18F]fluoro-L-dopa and [18F]fluorodeoxyglucose PET in Parkinson's disease. J Neurol 253: 340-348.
36. Breit S, Reimold M, Reischl G, Klockgether T, Wullner U (2006) [(11)C]d-threo-methylphenidate PET in patients with Parkinson's disease and essential tremor. J Neural Transm 113: 187-193. (Pubitemid 43121754)